[Clinical effectiveness of betahistine in monotherapy of vertigo for different etiology].
Vertigo is common symptom in clinical practice and among cerebrovascular and otological diseases. The aim of this clinical study was to evaluate the effect of betahistine dihydrochloride (Betaserc) on patients with long lasted dizziness. Enrolled in the study were 33 parients at the age between 32 and 80 years whom were treated 16 mg doses of betaserc three times daily et the time 12 weeks. The methods of following investigation was clinical examination, subjective and objective examination and carry out individual questionnaires once a four weeks. On the basis of experiment it was showed that a distinct clinical improvement in the group of 33 patients was in above 66% patients and medication is well tolerated and suitable for long-term treatment.
Nowak
Katarzyna
K
Klinika Otolaryngologii i Onkologii Laryngologicznej AM w Poznaniu.
Szymiec
Eugeniusz
E
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001621:Betahistine / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D012107:Research Design; D012680:Sensitivity and Specificity; D012720:Severity of Illness Index; D016896:Treatment Outcome; D014665:Vasodilator Agents / Q000008:administration & dosage*; D014717:Vertigo / Q000175:diagnosis* / Q000188:drug therapy*
D014665:Vasodilator Agents; D001621:Betahistine